Novellia Raises $18M for Patient-Controlled Health Data Platform

Why It Matters

The infusion of capital accelerates scaling of a patient‑centric data network, giving biopharma richer real‑world evidence while empowering individuals to own and monetize their health information—a shift reshaping digital health economics.

Key Takeaways

• $18M Series A led by Spark Capital boosts Novellia's runway
• Platform aggregates records, enabling patient‑controlled sharing with researchers
• De‑identified data sold to top pharma and diagnostics firms
• Focus on AI infrastructure to deliver richer real‑world evidence
• Targeting GLP‑1, cardiometabolic, rare disease markets with sparse data

Pulse Analysis

The push for patient‑controlled health data has moved from niche pilots to mainstream investment, spurred by regulatory frameworks like the CMS Interoperability Framework. By standardizing data exchange and encouraging vendor collaboration through tools such as Slack channels, the government is creating a fertile environment for platforms that give individuals direct access to their medical records. Investors see this as a gateway to unlock untapped real‑world evidence, and Novellia’s recent funding reflects that confidence.

Novellia’s platform combines a mobile app with AI‑driven analytics to pull disparate health records into a single, user‑friendly dashboard. Once aggregated, the data can be anonymized and sold to leading pharmaceutical and diagnostics companies, providing them with high‑quality, patient‑derived insights that are often missing from traditional clinical trials. The company’s focus on therapeutic areas where patient populations are small—such as rare cancers and emerging GLP‑1 treatments—positions it to fill a critical data gap, enabling faster drug development and more precise targeting.

For the broader digital health ecosystem, Novellia’s growth signals a maturation of the data‑exchange market. As more patients adopt the platform, network effects will enhance data richness, attracting additional pharma partners and potentially driving down the cost of real‑world evidence. Competitors will need to match its AI capabilities and patient‑trust model to stay relevant. The $18 million infusion not only fuels product enhancements but also underscores investor belief that patient‑owned data will become a cornerstone of future healthcare innovation.